Abstract
Rationale
Paroxetine may decrease mental stress-induced cardiovascular responses and so benefit individuals with heart disease, even those with no psychiatric illness.
Objectives
The effects of paroxetine on cardiovascular measures during a speech task were evaluated in psychiatrically healthy subjects with a history of coronary artery disease (CAD).
Methods
Eight subjects completed this double-blind, placebo-controlled, cross-over study in which each subject took 1 month of paroxetine and 4 weeks of placebo in random order. While on each study, medication, blood pressure, heart rate, and plasma norepinephrine concentrations were measured during a period of relaxation and during a mental stressor. The mental stressor consisted of thinking about a stressful topic, speaking about the topic, and listening to a tape-recorded replay of the speech.
Results
While on paroxetine, systolic blood pressure and diastolic blood pressure were 10–15% lower (p<0.005) during the stressor, relative to measures obtained while on placebo. Pulse and plasma norepinephrine concentrations during stress trended lower during paroxetine treatment but did not reach statistical significance.
Conclusion
Paroxetine has antihypertensive properties during periods of psychological stress in psychiatrically healthy subjects with a history of CAD, and so should be evaluated for potential cardio-protective qualities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvarez W Jr, Pickworth KK (2003) Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 23:754–771
Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Beasley C (1999) Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 19:9–14
Antonaccio MJ, Robson RD (1973) Cardiovascular effects of 5-hydroxytryptophan in anaesthetized dogs. J Pharm Pharmacol 25:495–497
Blatt CM, Rabinowitz SH, Lown B (1979) Central serotonergic agents raise the repetitive extrasystole threshold of the vulnerable period of the canine ventricular myocardium. Circ Res 44:723–730
Blumenthal JA, Jiang W, Waugh RA, Frid DJ, Morris JJ, Coleman RE, Hanson M, Babyak M, Thyrum ET, Krantz DS et al (1995) Mental stress-induced ischemia in the laboratory and ambulatory ischemia during daily life. Association and hemodynamic features. Circulation 92:2102–2108
Davidson JR, Potts NL, Richichi EA, Ford SM, Krishnan KR, Smith RD, Wilson W (1991) The brief social phobia scale. J Clin Psychiatr 52(Suppl):48–51
DeVane CL, Ware MR, Emmanuel NP, Brawman-Mintzer O, Morton WA, Villarreal G, Lydiard RB (1999) Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. Int Clin Psychopharmacol 14:345–351
Flockhart DA, Tanus-Santos JE (2002) Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 162:405–412
Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, McLvor M (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701–709
Goldberg AD, Becker LC, Bonsall R, Cohen JD, Ketterer MW, Kaufman PG, Krantz DS, Light KC, McMahon RP, Noreuil T, Pepine CJ, Raczynski J, Stone PH, Strother D, Taylor H, Sheps DS (1996) Ischemic, hemodynamic, and neurohormonal responses to mental and exercise stress. Experience from the Psychophysiological Investigations of Myocardial Ischemia study (PIMI). Circulation 94:2402–2409
Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1999) Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 19:23S–35S
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Jiang W, Babyak M, Krantz DS, Waugh RA, Coleman RE, Hanson MM, Frid DJ, McNulty S, Morris JJ, O'Connor CM, Blumenthal JA (1996) Mental stress-induced myocardial ischemia and cardiac events. JAMA 275:1651–1656
Kirschbaum C, Pirke KM, Hellhammer DH (1993) The ‘Trier Social Stress Test’—a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28:76–81
Krantz DS, Santiago HT, Kop WJ, Bairey Merz CN, Rozanski A, Gottdiener JS (1999) Prognostic value of mental stress testing in coronary artery disease. Am J Cardiol 84:1292–1297
Manuck SB, Olsson G, Hjemdahl P, Rehnqvist N (1992) Does cardiovascular reactivity to mental stress have prognostic value in postinfarction patients? A pilot study. Psychosom Med 54:102–108
Marais GE, Verrier RL, Lown B (1981) Mechanisms mediating the protective effects of central serotonergic agonists on vulnerability to ventricular fibrillation in the normal and ischemic heart (abstract). Circulation 64:320
Masand PS, Gupta S (1999) Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 7:69–84
Rabinowitz SH, Lown B (1978) Central neurochemical factors related to serotonin metabolism and cardiac ventricular vulnerability for repetitive electrical activity. Am J Cardiol 41:516–522
Sheps DS, McMahon RP, Becker L, Carney RM, Freedland KE, Cohen JD, Sheffield D, Goldberg AD, Ketterer MW, Pepine CJ, Raczynski JM, Light K, Krantz DS, Stone PH, Knatterud GL, Kaufmann PG (2002) Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation 105:1780–1784
Straneva P, Schwartz S, Gibson D, Golding M, Lee R, Girdler S (2001) Effects of two classes of antidepressant medications on cardiovascular reactivity to laboratory stress (abstract). Psychosom Med 63:144–145
Straneva-Meuse PA, Light KC, Allen MT, Golding M, Girdler SS (2004) Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients. J Affect Disord 79:51–61
Strike PC, Steptoe A (2003) Systematic review of mental stress-induced myocardial ischaemia. Eur Heart J 24:690–703
Tucker P, Smith KL, Marx B, Jones D, Miranda R, Lensgraf J (2000) Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol 20:367–372
Verrier RL (1986) Neurochemical approaches to the prevention of ventricular fibrillation. Fed Proc 45:2191–2196
Acknowledgements
Supported in part by a grant from the Foundation of Hope, Raleigh, NC, and by a grant from the General Clinical Research Centers program of the Division of Research Resources National Institutes of Health (RR00046).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Golding, M., Kotlyar, M., Carson, S.W. et al. Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses. Psychopharmacology 182, 321–326 (2005). https://doi.org/10.1007/s00213-005-0075-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-005-0075-7